ZBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zimmer Biomet Holdings, Inc. (ZBH) is not a strong buy for a beginner, long-term investor at this time. The stock shows limited near-term upside potential, and analysts have mixed to negative sentiment. Financial performance has been weak, with declining net income and EPS. The options data and technical indicators do not suggest a strong entry point. Given the investor's preference for long-term growth, it is better to hold off on buying until there is more clarity on the company's growth trajectory and execution improvements.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 63.224, and moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 96.696), suggesting limited upside in the short term.
The company beat Q4 2025 estimates amid low expectations, as noted by Citi. TD Cowen upgraded the stock to Buy, citing an improving growth and profit story.
Analysts have expressed concerns about limited product cycles, salesforce changes, and execution issues. The company's near-term growth is sensitive to market share shifts and pricing. Financial performance has been weak, with significant declines in net income and EPS.
In Q4 2025, revenue increased by 10.90% YoY to $2.24 billion. However, net income dropped by 41.84% YoY to $139.3 million, and EPS fell by 41.67% to $0.7. Gross margin also declined by 10.19% to 56.77%.
Analysts have mixed to negative views. Recent ratings include Market Perform and Neutral, with limited upside potential noted. Price targets range from $86 to $109, with several downgrades and cautious outlooks for 2026.
